WHO secures three licensing deals to boost Covid vaccine and assay product options
29 Aug 2023
VaccineLicense out/inEmergency Use AuthorizationmRNA
The World Health Organization has
secured
licensing agreements with Medigen Vaccine Biologics, the University of Chile and the Spanish National Research Council (CSIC) to increase the number of Covid-19 vaccine and assay product options for worldwide use. The licensing agreements fall under WHO’s Covid-19 Technology Access Pool (C-TAP).
Medigen is the first private manufacturer, as well as the first vaccine maker, to enter an agreement with C-TAP. The Taiwan-based biotech is licensing its Covid-19 vaccineCovid-19 vaccine, MVC COVID-19, and providing staff training to manufacturers. The protein subunit vaccine, which has emergency use authorization in Taiwan, has had three million doses administered in seven countries, according to a WHO press release.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.